Back to search
FDAFDA · Food and drugs·Recall number D-0774-2026

Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx only, Mylan Pharmaceuticals Inc., Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 266505, NDC 0378-6333-80.

Published August 26, 2026 · Recall initiated: July 24, 2026

Summary

FDA records drug Class II recall D-0774-2026, published August 26, 2026 and initiated July 24, 2026. Recalling firm: Mylan Pharmaceuticals Inc; Status: Ongoing; Lot: Lot# 3227809; Expiry:10/2026; NDC #: 0378-6333-80. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if ACAMPROSATE CALCIUM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ACAMPROSATE CALCIUM
Manufacturer
Mylan Pharmaceuticals Inc
Distributor
US Nationwide.
UPC
0303786333806
Lot
Lot# 3227809; Expiry:10/2026; NDC #: 0378-6333-80
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx only, Mylan Pharmaceuticals Inc., Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 266505, NDC 0378-6333-80. recalled?

Yes. FDA published recall D-0774-2026 on August 26, 2026. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ACAMPROSATE CALCIUM. UPC: 0303786333806.